Host immunologic augmentation for the control of infection

Infectious Disease Clinics of North America

Volumn 10, Issue 2, 1996, Pages 345-364

  Wingard, J R ^a   Elfenbein, G J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTIINFECTIVE AGENT; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; INTERFERON;

BACTERIAL INFECTION; CANCER; CELL PROLIFERATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESISTANCE; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; IMMUNOMODULATION; INFECTION CONTROL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MORBIDITY; MYCOSIS; NEUTROPENIA; REVIEW; RISK;

EID: 0029886782     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70302-0     Document Type: Article

References (111)

1. R. Advani N.J. Chao S.J. Horning Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma Ann Intern Med 116 1992 183 189
2. ASCO Ad Hoc Colony-Stimulating Factor Guideline Export Panel American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines J Clin Oncol 12 1994 2471 2508
3. E. Anaissie S. Vartivarian G.P. Bodey Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony stimulating factor ( E. coli -derived) in cancer patients with fever and neutropenia Am J Med 100 1996 17 23
4. Anaissie E, Wong E, Bodey GP, et al: Granulocyte macrophage colony stimulating factor plus amphotericin B for disseminated mycoses in neutropenic cancer patients [abstract 73]. In Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy of the American Society for Microbiology, Washington, DC, 1989, p 113
5. C. Anasetti G. Anderson F.R. Appelbaum Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors Blood 82 1993 454a
6. R.O. Bash J.A. Katz J.V. Cash Safety and cost-effectiveness of early discharge of relatively low risk children with cancer hospitalized for fever and neutropenia (F/N) [abstract] Proc Am Soc Clin Oncol 11 1991 381
7. E.B. Bass N.R. Powe S.N. Goodman Efficacy of intravenous immune globulin in preventing complications of bone marrow transplantation: A meta analysis Bone Marrow Transplant 12 1993 273 282
8. J. Beyer N. Schwella J. Zingsern Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison J Clin Oncol 12 1995 1328 1335
9. B. Biesma E.G. de Vries P.H. Willemse Efficacy and tolerability of recombinant human granulocyte-macrophage colony stimulating factor in patients with chemotherapy-related leukopenia and fever Eur J Cancer 26 1990 932 936
10. D. Blaise J.P. Vernant D. Fiere A randomized, controlled, multicenter trial of recombinant human granulocyte colony stimulating factor (filgrastim) in patients treated by bone marrow transplantation (BMT) with total body irradiation (TBI) for acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) [abstract] Blood 80 1992 982a
11. R.A. Bowden S.J. Slichter M.H. Sayers Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant Blood 78 1991 246 250
12. N.C. Bratanow R.C. Ash P.A. Turner Successful treatment of serious cytomegalovirus (CMV) disease with 9(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir), DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients [abstract 254] Exp Hematol 15 1987 541
13. M.K. Brenner D.R. Rill R.C. Moen Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 341 1993 85 86
14. E.R. Broun R. Gorin P. Kneebone Randomized trial of the addition of peripheral blood progenitor cells to autologous bone marrow in patients undergoing high dose chemotherapy with autologous progenitor support for breast and germ cell cancer Proc Am Soc Clin Oncol 13 1994 A1486
15. P.A. Bunn J. Crowley M. Hazuka The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG) [abstract] Proc Am Soc Clin Oncol 11 1992 292
16. A. Casadevall M.D. Scharff Return to the past: The case for antibody-based therapies in infectious diseases Clin Infect Dis 21 1995 150 161
17. H.M. Chapel M. Lee R. Hargreaves Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma Lancet 343 1994 1059 1063
18. K. Cohen L. Stork J. Cullen Discontinuation of antibiotics before neutrophil recovery in patients with febrile neutropenia (FN) and no identifiable source [abstract] Proc Am Soc Clin Oncol 11 1992 380
19. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia N Engl J Med 319 1988 902 907
20. J. Crawford H. Ozer R. Stoller Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHuG-CSF) N Engl J Med 325 1991 164 170
21. B. Davis L. Balart E. Schiff Hepatitis interventional therapy group. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter, randomized, controlled trial N Engl J Med 321 1989 1501 1506
22. E.G.E. de Vries B. Biesma P.H.B. Willemse A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma Cancer Res 51 1991 116 122
23. T. DeWitte A. Gratwohl N. Van Der Lely Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation Blood 79 1992 1359 1365
24. G.J. Elfenbein Hematopoietic stem cells for transplantation: Marrow or peripheral blood? Cancer Control 1 1994 188 189
25. Elfenbein GJ, Janssen WE, Perkins JB: Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man: Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. In Sackstein R, Janssen WE, Elfenbein GJ (eds): Annals of the New York Academy of Sciences. New York, in press
26. G. Elfenbein J. Krischer R. Babington Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation Transplant Proc 21 1989 3099 3100
27. G.J. Elfenbein J.B. Perkins K.K. Fields Hematologic recovery after high dose Taxol, Novantrone, thiotepa (TNT) and autologous stem cell transplant: Evaluation of the effects of stem cell source and Taxol Blood 84 suppl 1 1994 707a
28. D. Emanuel I. Cunningham K. Jules-Elysee Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin Ann Intern Med 109 1988 777 782
29. D. Fennelly L. Vahdat J. Schneider High-intensity chemotherapy with peripheral blood progenitor cell support Semin Oncol 21 suppl 2 1994 21 25
30. K.K. Fields G.J. Elfenbein H.M. Lazarus Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile J Clin Oncol 13 1995 3223 3332
31. K.K. Fields G.J. Elfenbein J.B. Perkins High-dose ifosfamide/carboplatin/etoposide: Maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion Semin Oncol 21 suppl 12 1994 86 92
32. K.K. Fields G.J. Elfenbein J.B. Perkins Two novel high dose treatment regimens for metastatic breast cancer: Ifosfamide carboplatin plus etoposide (ICE) and mitoxantrone plus thiotepa (MITT): Outcomes and toxicities Semin Oncol 20 suppl 6 1993 59 66
33. K. Fields J. Perkins G. Elfenbein A phase I dose escalation trial of high dose Taxol, Novantrone and thioTEPA (TNT) followed by autologous stem cell rescue (ASCR): Toxicity Proc Am Soc Clin Oncol 14 1995 322
34. K.K. Fields J.B. Perkins G.J. Elfenbein Reply to Letter-to-the-Editor J Clin Oncol 13 1995 1826 1827
35. J.L. Gabrilove A. Jakubowski H. Scher Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium N Engl J Med 318 1988 1414 1422
36. V. Gebbia A. Testa R. Valenza A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma J Chemother 5 1993 186 190
37. H.H. Gerhartz M. Engelhard P. Meusers Randomized, double-blind, placebo-controlled Phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [abstract] Blood 82 1993 2329 2339
38. Gilmore CE, Dix SP: Cytokine therapy following bone marrow transplantation: Review of GM-CSF and G-CSF. Pharmacotherapy, in press
39. J. Glaspy G. Bleecker J. Crawford The impact of therapy with recombinant granulocyte colony stimulating factor (G-CSF) on the health care costs associated with cancer chemotherapy [abstract] Blood 78 1991 7a
40. J.A. Glaspy J. Jakway Cost considerations in therapy with myeloid growth factors Am J Hosp Pharm 50 1993 S19 S26
41. N.C. Gorin B. Coiffier M. Hayat Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged bone marrow in non-Hodgkin's lymphoma: A double-blind placebo-controlled trial Blood 80 1992 1149 1157
42. P. Greenberg K. Taylor R. Larson Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS) [abstract] Blood 82 1993 196a
43. T.C. Griffin G.R. Buchanan Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital J Pediatr 121 1992 28 33
44. S. Gulati C. Bennett Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease Ann Intern Med 116 1992 177 182
45. P. Gupta C. Tiley R. Powles No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation Bone Marrow Transplant 9 1992 491 493
46. J.T. Hamm J.H. Schiller M.M. Oken Dose ranging study of recombinant human granulocyte-macrophage colony stimulating factor in small cell lung cancer [abstract] Proc Am Soc Clin Oncol 12 1993 335
47. J.T. Hamm J.H. Schiller M.M. Oken Granulocyte-macrophage colony-stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCCL): Preliminary analysis of a randomized controlled trial [abstract] Proc Am Soc Clin Oncol 10 1991 255
48. G. Heil L. Chadid D. Hoelzer GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML) Leukemia 9 1995 3 9
49. J.W. Hiemenz R. Bowden Infectious complications after ablative therapy and autologous or allogeneic marrow transplantation Infect Dis Clin North Am 10 1996 in press
50. W.T. Hughes D. Armstrong G.P. Bodey Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever J Infect Dis 161 1990 381 396
51. W.E. Janssen R.C. Smilee G.J. Elfenbein A prospective randomized trial comparing blood vs. marrow derived stem cells for hematopoietic replacement following high dose chemotherapy J Hematother 4 1995 139 140
52. L.D. Kaplan J.O. Kahn F. Crowe Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial J Clin Oncol 9 1991 929 940
53. A. Khwaja D.C. Linch A.H. Goldstone Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A British National Lymphoma Investigation double-blind, placebo-controlled trial Br J Haematol 82 1992 317 323
54. M. Korbling P. Burke H.G. Braine Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia Exp Hematol 9 1981 684 690
55. D.C. Linch H. Scarffe S. Proctor Randomised vehicle-controlled, dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after marrow transplantation Bone Marrow Transplant 11 1993 307 311
56. H. Link M.A. Boogaerts A.M. Carella A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma Blood 80 1992 2188 2195
57. S.G. Louie B. Jung Clinical effects of biologic response modifiers Am J Hosp Pharm 50 1993 S10 S18
58. G.H. Lyman C.G. Lyman R.A. Sanderson Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy J Natl Cancer Inst 85 1993 1935 1936
59. D. Maher M. Green J. Bishop Randomized, placebo-controlled trial of filgrastim (r-metHuG-CSF) in patients with febrile neutropenia (FN) following chemotherapy (CT) [abstract] Proc Am Soc Clin Oncol 12 1993 434
60. T. Masaoka Y. Moriyama S. Kato A randomized, placebo-controlled study of KRN8601 (recombinant human granulocyte colony-stimulating factor) in patients receiving allogeneic bone marrow transplantation Jpn J Med 3 1990 233 239
61. J.I. Mayordomo F. Revera M.T. Diaz-Puente Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: Results of a randomized trial [abstract] Proc Am Soc Clin Oncol 12 1993 437
62. A. Messori R. Rampazzo G. Scroccaro N. Martini Efficacy of hyperimmune anticytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: A meta-analysis Bone Marrow Transplant 13 1994 163 167
63. J.D. Meyers N. Fournoy J.E. Sanders Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation Ann Intern Med 107 1987 809 816
64. C.A. Mullen G.R. Buchanan Early hospital discharge of children with cancer treated for fever and neutropenia. Identification and management of the low-risk patient J Clin Oncol 8 1990 1998 2004
65. H.W. Murray Interferon-γ and host antimicrobial defense: Current and future clinical applications Am J Med 97 1994 459 467
66. J. Nemunaitis J.D. Meyers C.D. Buckner Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections Blood 78 1991 907 913
67. J. Nemunaitis S. Rabinowe J. Singer Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer N Engl J Med 324 1991 1773 1778
68. J. Nemunaitis C.R. Rosenfeld R. Ash Phase III, double blind placebo controlled trial of rhGM-CSF following allogeneic bone marrow transplant Bone Marrow Transplant 15 1995 949 954
69. C. Nichols D. Bajorin H.J. Schmoll VIP chemotherapy with/without GM-CSF for poor risk, relapsed, or refractory germ cell tumors (GCT): Preliminary analysis of a randomized controlled trial [abstract] Proc Am Soc Clin Oncol 10 1991 167
70. NIH Conference: Interferon-γ in the management of infectious diseases Ann Intern Med 123 1995 216 224
71. R. Ohno M. Tomonaga T. Kobayashi Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia N Engl J Med 323 1990 871 877
72. E.B. Papadoupoulos M. Ladanyi D. Emanuel Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation N Engl J Med 330 1994 1185 1191
73. R. Perillo E. Schiff G. Davis A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B N Engl J Med 323 1990 295 301
74. Perkins JB, Elfenbein GJ, Janssen WE, et al: G-CSF primed bone marrow and G-CSF primed peripheral blood stem cells vs chemotherapy primed peripheral blood stem cells: No engraftment advantage seen with combination. Experimental Hematology Today, in press
75. W.P. Peters G. Rosner M. Ross Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy Blood 81 1993 1709 1719
76. W.P. Petros W.P. Peters Hematopoietic colony-stimulating factors and dose intensity Semin Oncol 20 1993 94 99
77. R. Pettengell H. Gurney J.A. Radford Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial Blood 80 1992 1430 1436
78. R. Powles C. Smith S. Milan Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: Double-blind, placebo-controlled trial Lancet 336 1990 1417 1420
79. S.N. Rabinowe D. Neuberg P.J. Bierman Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies Blood 81 1993 1903 1908
80. E.C. Reed R.A. Bowden P.S. Dandliker Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous immunoglobulin in patients with bone marrow transplants Ann Intern Med 109 1988 783 788
81. S.R. Riddell P. Reusser P.D. Greenberg Cytotoxic T-cells specific for cytomegalovirus: A potential therapy for immunocompromised hosts Rev Infect Dis 13 1991 5966 5973
82. S.R. Riddel B.A. Walter M.J. Gilbert P.D. Greenberg Selective reconstitution of CD8+cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones Bone Marrow Transplant 14 1994 S78 S84
83. S.R. Riddel K.S. Watanabe J.M. Goodrich Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones Science 257 1992 238 244
84. P. Riikonen U.M. Saarinen A. Makipernaa rhGM-CSF in the treatment of fever and neutropenia: A double-blind, placebo-controlled study in children with malignancy [abstract] Proc Am Soc Clin Oncol 12 1993 442
85. E. Roilides P.A. Pizzo Perspectives on the use of cytokines in the management of infectious complications of cancer Clin Infect Dis 17 1993 S385 S389
86. E. Roilides K. Uhlig D. Venzon Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon Infect Immun 61 1993 1188 1193
87. K. Rolston E. Rubenstein S. Frisbee-Hume Outpatient treatment of febrile episodes in low-risk neutropenic cancer patients [abstract] Proc Am Soc Clin Oncol 12 1993 436
88. J.M. Rowe J. Anderson J.J. Mazza Phase III randomized placebo-controlled study of yeast derived GM-CSF in adult patients (55-70 years) with AML [abstract] Blood 82 1993 329a
89. E.B. Rubenstein K. Rolston R.S. Benjamin Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer Cancer 71 1993 3640 3646
90. S.E. Salmon B.A. Samai D.M. Hayes Role of gamma globulin for immunoprophylaxis in multiple myeloma N Engl J Med 227 1967 1336 1340
91. D.M. Schales B. Binczewski L.B. Rice Emerging antimicrobial resistance and the immunocompromised host Clin Infect Dis 17 1993 S527 S536
92. G.M. Schmidt A. Kovacs J.A. Zaia Ganciclovir/Immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients Transplantation 46 1988 905 907
93. N. Schmitz P. Dreger A. Zander Recombinant human granulocyte colony stimulating factor (filgrastim) after autologous bone marrow transplantation for lymphoma: An open label randomized trial in Germany [abstract] Blood 80 1992 292a
94. J.R. Schriber N.J. Chao G.D. Long Granulocyte colony stimulating factor after allogeneic bone marrow transplantation Blood 84 1994 1680 1684
95. M.W. Schuster R.A. Larson J.A. Thompson Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multicenter, randomized, controlled trial. [abstract] Blood 76 1990 318a
96. W.P. Sheridan C.G. Begley C.A. Juttner Effect of peripheral-blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating-factor for hematologic support after high-dose intensification for breast cancer Blood 79 1992 3036 3044
97. S.C. Shivers R. Carter G.J. Elfenbein W.E. Janssen Synergy between bone marrow (BM) cells and peripheral blood stem cells (PBSC) in the ability to form granulocyte/monocyte colony forming units (CFU-GM) in vitro Exp Hematol 22 1994 758
98. G. Spitzer D.R. Adkins V. Spencer Randomized study of growth factors post-peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit J Clin Oncol 12 1994 661 670
99. R.A. Stahel E. Muller G. Pichert Dose intensification with autologous marrow support in high-risk lymphoma: Acceleration of hematopoietic recovery and reduction of days of hospitalization with granulocyte colony-stimulating factor (G-CSF) in a randomized open-label trial [abstract] Proc Am Soc Clin Oncol 11 1992 331
100. R. Stone S. George D. Berg GM-CSF 'V' placebo during remission induction for patients ≥60 years old with de novo acute myeloid leukemia [abstract] Proc Am Soc Clin Oncol 13 1994 304
101. K.M. Sullivan K.H. Kopecky J. Jocum Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation N Engl J Med 323 1990 705 712
102. The International Chronic Granulomatous Disease Cooperative Study Group A controlled trial of interferon-γ to prevent infection in chronic granulomatous disease N Engl J Med 324 1991 509 516
103. A. Tomiak J. Yau S. Haun Duration of intravenous (IV) antibiotic and hospital stay for patients with febrile neutropenia after chemotherapy: Experience of Ottawa Regional Cancer Center [abstract] Proc Am Soc Clin Oncol 12 1994 435
104. V. Trillet-Lenoir J. Green C. Manegold Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29A 1993 319 324
105. P.J. Tutschka G.W. Santos G.J. Elfenbein Marrow transplantation in acute leukemia following busulfan and cyclophosphamide S. Thierfelder H. Rodt J.H. Kolb Immunobiology of Bone Marrow Transplantation 1980 Springer New York 375 380
106. Vadhan-Raj H.E. Broxmeyer W.N. Hittelman Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level J Clin Oncol 10 1992 1266 1277
107. J.C. Weeks M.R. Tierney M.C. Weinstein Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia N Engl J Med 325 1991 81 86
108. D.E. Williams Optimizing the effectiveness of hematopoietic growth factors J Clin Immunol 14 1994 215 223
109. D.J. Winston W.G. Ho R.E. Champlin Cytomegalovirus infections after allogeneic bone marrow transplantation Rev Infect Dis 12 1990 S776 S792
110. S.N. Wolff J.W. Fay R.H. Herzig High-dose intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy Ann Intern Med 118 1993 937 942
111. P.L. Yap Prevention of infection in patients with B cell defects: Focus on intravenous immunoglobulin Clin Infect Dis 17 1993 S372 S375